ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cornell, GSK Fund Drug Discovery

by Lisa M. Jarvis
March 3, 2014 | APPEARED IN VOLUME 92, ISSUE 9

In an effort to bridge the funding gap between early-stage drug discovery and clinical development, Weill Cornell Medical College has launched the Daedalus Fund for Innovation. An advisory committee that includes industry, venture capital, and Weill Cornell representatives will select projects proposed by medical college faculty; funding will be milestone driven. In a separate move, GlaxoSmithKline has put out a call for proposals for its 2014 Discovery Fast Track Challenge, a program that teams GSK scientists with academic researchers who have a hypothesis on a biological pathway or target. This year’s program expands beyond the U.S. and Canada to include Europe.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment